At a glance
ClinicalIndex Comparison Record- ✓Idiopathic Parkinson's disease with Hoehn and Yahr stage 2–3, presenting with gait freezing or postural instability
- ✓On stable dosage of dopamine agonist or levodopa, expected to remain unchanged for duration of study
- ✓Age less than 80 years with disease onset after age 45
- ✕History of seizures
- ✕History of renal insufficiency
- ✕History of cardiac arrhythmia
- ✕Severe arthritis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Ampyra first, then Placebo and placebo first, then Ampyra for Parkinson's Disease. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit from this medication and have major improvements in gait after taking this medication. However, this medication was never studied in Parkinson's disease. This study aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).
Study Details
Timeline
Interventions
10 mg po bid for 4 weeks followed by placebo 4 weeks.
placebo